Acute respiratory distress syndrome is an often fatal disease that develops after acute lung injury and trauma. 
Introduction
Acute lung injury (ALI) can result from direct injury caused by bacterial or viral pneumonia, aspiration, and toxin inhalation and indirect injury following sepsis, major trauma, and blood transfusion (1, 2) . ALI may lead to the more severe acute respiratory distress syndrome (ARDS) that has a complex pathology and causes considerable morbidity and mortality (3, 4) . Diffuse alveolar damage, pulmonary edema and hypoxemia due to dysregulated inflammation, reflected by increased inflammatory cytokines in the plasma or bronchoalveolar lavage fluid (BALF) and accumulation of extravascular neutrophils, are defining features of ARDS (2, 5) . In addition to neutrophils, macrophages and monocytes also play a causal role in ARDS, as they initiate and perpetuate lung damage through contributing to the local inflammation that causes increased epithelial and endothelial permeability (6) (7) (8) . Despite intensive basic and clinical study over the past several decades, there remains a lack of effective treatments to prevent or resolve ARDS (2, (9) (10) (11) (12) (13) (14) (15) (16) (17) . Thus, the risk of mortality remains high for ARDS patients (4, 18) . Lung-protective mechanical ventilation and conservative fluid management reduce inflammatory cytokine levels and neutrophil numbers in the BALF of animals subjected to ALI and ALI/ARDS patients (19, 20) . To date, these supportive procedures that reduce early inflammation are the only means to provide consistent improvement in patient outcome (4, 18) .
The pathophysiology of ALI is commonly studied in rodent models where instillation of chemicals, such as bleomycin (bleo), damages the epithelial and endothelial barriers, thus increasing alveolar-capillary permeability that results in fluid and protein accumulation in the alveolus (21) (22) (23) (24) . The BALF isolated in the first several days of bleo-induced ALI contains high levels of neutrophils and inflammatory cytokines, including IL-1b, IL-6, TNF and monocyte chemoattractant protein 1 (MCP-1)/CCL2 (22, 23, 25) . Infiltrating inflammatory monocytes, monocyte-derived interstitial macrophages and residential alveolar macrophages (AM) are present and thought to contribute to the early inflammatory response and tissue damage after experimental ALI, including that induced by bleo (6, 26) . These same cells, however, also participate in inflammation and injury resolution, as well as the development of subsequent fibrotic disease after ALI (6, 27, 28) . Foxp3 + Treg have also been implicated in the resolution of ALI by shaping alveolar cytokines, potentially by modulating those produced by macrophages (29) . Recently, Misharin et al. revealed that the primary drivers of lung fibrosis following tissue injury are monocyte-derived AM that rapidly replace depleted fetal-derived tissue-resident AM after bleo (30) . Gaining an understanding of the endogenous mechanisms controlling early inflammation and shifting the local environment, including resident and infiltrating myeloid cells, away from an inflammatory state and towards one of rapid resolution and effective repair after ALI could lead to novel therapies that can prevent or rapidly resolve ALI/ARDS, as well as reduce subsequent fibrosis.
Tissue injury associated with trauma leads to the release of alarmins, or self-molecules that alert the immune system to damage (31) (32) (33) (34) . One alarmin of particular interest is IL-33, which is highly expressed in the lungs of mice and humans (35) . While IL-33 supports inflammatory responses to parasites, it also drives allergic airway disease and fibrosis of the lung and other organs (35) (36) (37) (38) (39) . However, Treg that express the IL-33 receptor, serum stimulation-2 (ST2, encoded by Il1rl1), upregulate amphiregulin after IL-33 stimulation and this mechanism has been implicated recently in epithelial tissue repair after viral infection of the lung (40) . Related in vitro studies have suggested that IL-33 potentiates the suppressive capacity of Treg (41) . After muscle injury, the presence of ST2 + Treg have been associated with the transition of infiltrating myeloid cells from a proinflammatory subset to a reparative/regenerative subset (42) . Mechanisms by which IL-33 stimulation of ST2 + Treg to local control of myeloid cell function or differentiation, however, are unknown. These studies proposing the regulatory or reparative activity of IL-33 are in direct contrast to other investigations that suggest IL-33 causes functional dysregulation in Treg in the lung (43) and skin (44) . This dysregulation is associated with the lost capacity to suppress (Teff)
T cell proliferation and pathological induction of Type 2 cytokine production (43, 44) . Accordingly, the role of IL-33 in acute organ injury is unclear and the mechanisms, especially involving Treg, by which IL-33 may shape early inflammation or contribute to injury resolution are poorly defined.
The goal of the current studies was to establish how IL-33 impacts Treg after bleo-induced ALI and to ascertain the role that this interaction plays in shaping the early inflammatory environment. In doing this, we made the unanticipated discovery that IL-33 is critical to prevent mortality after ALI by controlling the early inflammatory response after tissue injury through its actions on Treg. Mice deficient in IL-33 were found to be more susceptible to lung damage-associated lethality, which is typified by augmented levels of inflammatory cytokines and immune cell infiltration. We then established the mechanism underlying IL-33 control of the local inflammatory immune response after ALI involves the induction of the IL-13 production by ST2 + Treg that served to limit local inflammatory cytokines and the presence of inflammatory myeloid cells. In total, we establish an important protective and immunoregulatory capacity of IL-13 and IL-33 after lung injury that supports resolution of the inflammation associated with ALI. Given that inflammatory responses are considered primary drivers of ARDS, IL-13, IL-33 or IL-33-stimulated Treg secreting IL-13 may be novel therapeutic targets to further evaluate early after ALI.
Results

IL-33 deficiency results in an impaired ability to survive acute lung injury (ALI) induced by bleomycin (bleo)
Augmenting IL-33 in IL-33 replete mice via delivery of the recombinant (r) protein or inducing over expression by adenoviral vectors has been suggested to augment the development of fibrosis after bleo administration (45, 46 ). Yet the impact of endogenous IL-33 after bleo-induced ALI is poorly understood. When compared to wild-type (WT) mice after intratracheal (i.t.) bleo-induced chemical ALI, Il33 -/-mice exhibited a more substantial loss of body weight ( Figure 1A) and the lack of IL-33 accelerated the death of Il33 -/-mice ( Figure 1B ) compared to WT. Histological examination revealed that the reduced survival of Il33 -/-mice was associated with increased lung pathology and inflammation ( Figure 1C ).
Histology scored on day 7 following i.t. bleo revealed that Il33 -/-mice had significant increases in perivascular and peribronchiolar inflammation ( Figure 1C and D) . Likewise, lungs from Il33 -/-mice had markedly increased levels of intraalveolar macrophage infiltration and early fibrosis compared to WT mice ( Figure 1C and D) . Computerized calculation of total lung consolidation suggested a more significant loss of functional lung area in Il33 -/-mice ( Figure 1D ). IL-33 deficient mice also displayed a slight trend towards increased levels of total protein in BALF at days 7-8 post bleo (Supplemental Figure 1A) . Surviving Il33 -/-mice on day 13 also displayed increased levels of hydroxyproline that was consistent with the early increase in fibrosis identified by histopathology (Figure 1C and D; Supplemental Figure 1B) . Together, these data suggest a role for endogenous IL-33 in the protection of mice from mortality after bleo-induced ALI. Also, as the course of the immune response to bleo injury to the lung is well-studied and described, it was apparent that IL-33-deficient mice were dying during the peak of the inflammatory immune response (47, 48) .
Evidence for increased inflammation after ALI in the absence of IL-33
We next verified that restoration of IL-33 could protect Il33 -/-mice from early mortality following bleo challenge. While a onetime instillation of rIL-33 at the time of 1.5 IU/kg i.t. bleo did not rescue Il33 -/-mice (data not shown), rIL-33 treatment did rescue a significant percentage of mice from mortality after 1.0 IU/kg bleo-induced lung injury (Figure 2A) . At this dose of bleo, Il33 -/-mice again displayed an accelerated death rate relative to WT mice (Figure 2A ).
Given the apparent failure of Il33 -/-mice to control or resolve the inflammatory response after injury, we next sought to define how restoration of IL-33 altered the local immune and cytokine environment early after bleo-induced lung injury. Luminex quantification of BALF cytokines revealed that IL-33 was a negative regulator of IL-6, granulocyte colonystimulating factor (G-CSF), MCP1/CCL2, leukemia inhibitory factor (LIF), and IL-1a in samples collected on days 7 and 8 post bleo insult ( Figure 2B ). While detected, we did not observe significant differences between WT and Il33 -/-BALF levels of Eotaxin/CCL11, IL-5, IL-9, CXCL10, CXCL1, and CXCL9 (data not shown). Granulocyte-macrophage colonystimulating factor, IFNg, IL-1b, IL-2, IL-3, IL-4, IL-7, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, and CXCL5 were not detected in the BALF at this time point (data not shown).
When the cellular infiltrates present in the BALF of Il33 -/-mice at day 7 and 8 post bleo were compared to that of WT by flow cytometry, it was found that the BALF of Il33 -/-mice had significantly increased frequency of neutrophils Figure 2D ). An increase in Ly6C lo monocytes frequency relative to that of Ly6C hi monocytes in sites of injury is correlated with tissue repair and inflammation resolution (28, 42, 49) . Interestingly, delivery of IL-33 at the time of bleo insult potently increased the frequency, but not total number, of Ly6C lo monocytes in the BALF ( Figure 2D and Supplemental Figure   2C ). Our data generated on day 7 and 8 after bleo injury are consistent with IL-33 acting as crucial local factor that limits and qualitatively shapes the early inflammatory response after ALI. Figure 3A-B) . We also established that a lack of IL-33 did not significantly reduce the frequency of interstitial Treg at day 8 post bleo delivery relative to WT lungs, although delivery of rIL-33 increased the frequency of ST2 + Treg in the lung (Figure 3A-B Figure 3C ). Thus, we demonstrated the protective capacity of local IL-33 against bleo-induced ALI in a second strain combination. We also verified that there were comparable rates of DT-mediated depletion between mice treated with IL-33 and those left untreated (Supplemental Figure 5) . As expected (29) , Treg-depleted mice display increased susceptibility to death after bleo compared to Treg replete mice ( Figure 3C ). IL-33-treated, Treg-depleted mice had a slight, but non-significant increase in survival after i.t. bleo suggesting a minimal role for ILC2 in IL-33-mediated protection early after ALI. In total, these data support the importance of IL-33 action on Treg for a protective function following ALI. (41) and IL-13, which has been suggested to result in a pathophysiologic role for Treg during the development of allergic airway disease (43) .
IL-33 protective function following ALI is mediated by regulatory T cells
rIL-33 enhances expansion of suppressive IL-13-secreting human Treg
We next determined whether rIL-33 facilitated these effects in human Treg. We have established previously that the addition Figure 5D ). We also verified that Treg cultured with IL-33 expressed a high level of Foxp3 (Supplemental Figure 6B ) and established that the IL-13 production was restricted to Foxp3 hi T cells ( Figure 5E and Supplemental Figure 6C ). In total, our data support the capacity of IL-33 to mediate the production of IL-13 by suppressive mouse and human Treg.
Treg secretion of IL-13 is required to protect mice from mortality after ALI
To determine if IL-33-mediated local IL-13 secretion may have any protective function against ALI mortality we administered rIL-13 i.t. in conjunction with bleo challenge of Il33 -/-mice and found that rIL-13 significantly improved their survival ( Figure 6A ). When we delivered rIL-13 with IL-33 to Treg-depleted Foxp3 DTR B6, we also found that rIL-13 significantly prolonged mouse survival after bleo injury ( Figure 6B ). These data suggest that IL-13 secreted by Treg acts as a critical factor in the protective capacity of IL-33 after ALI.
To establish more precisely the role of Treg-secreted IL-13 in protection against ALI-induced mortality, we crossed Figure 7C) . Thus, the deletion of IL-13 from Treg does not appear to alter their suppressive capacity. Figure 6C-D) . The dose of bleo was increased to 6.0 IU/Kg in these studies to account for the BALB/c background of the Figure 10A) , which was not due to altered viral clearance (Supplemental Figure 10B) . Likewise, Foxp3
Cre x Il4/Il13 fl/fl mice also again had an increased frequency of inflammatory monocytes at day 7 post infection (Supplemental Figure 10D ). In total our data generated using this novel mutant Treg mouse in two distinct models of ALI support a critical role for IL-13 secreted by Treg for regulation of the early inflammatory response, especially the accumulation of neutrophils and inflammatory monocytes after lung injury.
Arginase 1 (Arg1) is commonly expressed by immunoregulatory or reparative myeloid cells (62) (63) (64) Figure 6G , Column #5). These data suggest that ST2 + Treg can be stimulated by IL-33 to support the differentiation of myeloid cells towards that of those with reparative or regulatory functions, such as myeloid-derived suppressor cells (MDSC) or reparative macrophages (62) (63) (64) . This capacity was reduced significantly when IL-13 was deleted from Foxp3-expressing cells ( Figure 6G , Column #7). These data suggest that IL-33-mediated Treg secretion of IL-13, while not important for suppressive function, may act as a potent modulator of infiltrating myeloid cells after tissue injury.
Discussion
We have made several novel and impactful findings in the current studies. First, by demonstrating the sensitivity of IL-33 deficient mice to bleo-induced ALI and the reversibility of this phenotype by complementation with rIL-33, we have established that IL-33 is a crucial local factor necessary to limit the early inflammatory response after chemically-induced ALI. Second, we found that Treg are the cellular mediator of the protective capacity of IL-33 after ALI. Third, we identified that IL-33-stimulated IL-13 production by Treg is critical for controlling inflammation after chemically-and virally-induced ALI and can shape macrophage activation ex vivo.
Our observations may seem counterintuitive given the compelling evidence for a pathological role for IL-13 in tissue fibrosis and asthma development (65) (66) (67) (68) ). Yet, IL-13 has also become known for regenerative and reparative functions, due in large part to its capacity to activate tissue-repair macrophages (62, (69) (70) (71) . Recently, it was demonstrated that ILC2-produced IL-13 promotes lung regeneration after pneumonectomy by stimulating macrophage support of Type 2 alveolar epithelial stem cell proliferation (72) . GVHD studies demonstrate potent protective capacities of ILC2-secreted IL-13, which diminished Th1 and Th17 responses, generated MDSC, aided gastrointestinal homeostasis, and promoted animal survival (73) . IL-13 administration to GM-CSF and G-CSF-driven bone marrow cultures generates Arg1 + MDSC able to limit GVHD lethality through immune regulation (74) . Our current study establishes that in the absence of IL-13-expression by Treg, ALI results in increased lethality associated with augmented frequency of phenotypic inflammatory monocytes.
We also find that IL-33-stimulated Treg secreting IL-13 directly induces Arg1 gene expression in splenic macrophages.
These data are similar to recent ex vivo studies demonstrating that Treg-produced IL-13 stimulates IL-10 production in interacting macrophages to support macrophage efferocytosis of apoptotic cells (75) . Together, our studies define an important role for IL-33-stimulation of Treg secretion of IL-13 for control of the myeloid response and inflammation after injury.
Peripheral tissues, including the lung, have higher frequencies of ST2 + Treg relative to the secondary lymphoid organs (SLO) (Supplemental Figure 3C ) and (42, 55, 76 ). Yet, due to the greater overall immune cell number of the spleen, the incidence of ST2 + Treg in the spleen is comparatively quite high relative to the lung. Importantly, unlike macrophages, there is no existing evidence suggesting that Treg within peripheral tissues are embryonically distinct from those of SLO (77, 78) . Therefore, we chose to compare splenic ST2 + vs. ST2 -Treg in the mechanistic and characterization studies requiring high cell numbers. Consistent with our previous findings (54) and those of others (55, 79), ST2 + Treg from both lymphoid and non-lymphoid tissues showed higher expression of activation markers including, CD44, CD103 and killer cell lectin-like receptor subfamily G member 1 (KLRG1), and suppressor functional molecules such as OX40 and glucocorticoid-induced TNFR-related protein (GITR), compared with ST2 -Treg (Supplemental Figure Fig. 3D This knowledge may allow development of therapies designed to augment required Treg functions or lead to novel cell therapies utilizing Treg generated specifically to perform repair, suppress myeloid cell inflammation, or control T effectors.
After alveolar barrier disruption, dysregulated inflammation and immune cell activity can lead to increased ALI pathology and ARDS (1, 2). Failure to rapidly resolve inflammation and associated tissue injury, support alveolar progenitor cell renewal, and direct appropriate regeneration of the alveolar epithelium can also lead to pulmonary fibrosis (87 Furthermore, we found that both IL-33 and IL-13-secretion by Treg modulated IL-6, G-CSF, and MCP-1/CCL2 after bleo-induced ALI. This is consistent with prior studies where CD4 + CD25 + T cells were demonstrated to suppress IL-6 and MCP-1/CCL2 after LPS-mediated ALI (29) . While it is tempting to conclude that a reduction of these effector molecules underlies the observed decrease in mortality after ALI, like IL-33 and IL-13, these molecules possess a pleotropic nature during ALI. IL-6 is a mediator of acute phase inflammation and orchestrates the immune responses leading to fibrosis after bleo insult (95, 96) , but IL-6 is also important for supporting alveolar progenitor renewal (97, 98) . Blocking G-CSF signaling reduces inflammation and MCP-1/CCL2 levels (99) . Monocyte recruitment to the inflamed lung is dependent on CCR2 and serves to accelerate and augment neutrophil accumulation (100, 101). Intra-peritoneal bleo delivery to Ccl2 mice fails to instigate the typical monocytic lung inflammation or cause significant lung fibrosis (102) . Sustained expression of MCP-1/CCL2 is associated with increased recruited macrophage in ARDS patients and worse prognosis (6, 103) . Thus, the local regulation of MCP-1/CCL2 by ST2 + Treg stimulated with released IL-33 could be an important mechanism to control pathology early after ALI. However, mice with lung-specific over expression of MCP-1/CCL2, however, display resistance to bleo-induced lung injury (104). This was due to an increased ability of MCP-1/CCL2 overexpressing mice to recruit a monocyte/macrophage subpopulation that mediates clearance of apoptotic neutrophils. As such, these mice could better complete a critical step in the initiation of inflammation resolution after ALI (2) . The complexity of the cytokine and immune cell networks that control an inter-related inflammatory and resolution/repair response are quite evident. It is safe to conclude that IL-33 is as an important tissue-derived signaling molecule that is active in both the inflammatory and resolution/repair phases after tissue injury. Our current studies place IL-33 upstream of a potent Treg response that dampens early inflammatory responses after injury and is required to survive an insult to the lung epithelium. It will now be important to use techniques such as bioinformatics and math modeling of the immune cell/cytokine interactions (92) 
Foxp3-IRES-Cre mice (BALB/c Foxp3
Cre ; (58)) were obtained from Dr. Dario Vignali (University of Pittsburgh).
Previously described BALB/c Il1rl1 -/-were obtained from Dr. Foo Yew Liew (University of Glasgow, UK) (51, 107). All mice were bred and/or maintained in a specific pathogen-free animal facility at the University of Pittsburgh. Flow Cytometry. Alveolar leukocytes were obtained by centrifugation of BALF collected using methods similar to those described (104, 108) . To assess interstitial leukocytes, mouse lungs were cut into small pieces and enzymatically digested using either collagenase D and DNase I (both from Sigma-Aldrich) or lung dissociation kit (Miltenyi Biotec) followed by mechanical dissociation in C tubes using a gentleMACS dissociator (Miltenyi Biotec). Single cell homogenates of splenocytes were generated for flow cytometric assessment using standard and widely published laboratory procedures. RNA-Seq and bioinformatics analyses. Splenic CD4 + T cells were obtained from B6 FIR mice using negative depletion with Dynabeads (Life Technologies) as we have described in detail (51). These cells were cultured for 5 days with BALB/c CD11c + bone marrow derived dendritic cells (BMDC) generated as we have described (54) in media supplemented with rIL-33 (20 ng/ml; Biolegend). Cultured cells were then stained with antibodies to CD4 and ST2, and the CD4 + Foxp3 + (RFP + ) ST2 + population flow sorted to >95% purity using a BD FACSAria. Sorted cells were rested for 15-18 h in complete RPMI at 5% CO2 and 37 o C, followed by a 6 hours period where they remained untreated or were stimulated with 100 ng/ml mouse rIL-33 during the culture period. Cells were collected and RNA extracted after lysing in TRIzol reagent Amino Acids, 10 mM HEPES, 1 mM sodium pyruvate, and 100 U/ml each of penicillin and streptomycin. Anti-CD28 (BD Biosciences, 2 μg/ml) and human rIL-2 (Peprotech, 50 U/ml) were added for T cell activation. Some wells were treated with 20 ng/ml mouse rIL-33. After 3 days, the culture supernatants were harvested and analyzed by Cytometric Bead Array *P<0.05, **P <0.01, ***P <0.001, ****P <0.0001. with diphtheria toxin (15 μg/Kg on day -3, -2 and -1, and every other day starting from day 1). Depicted data represent 1 experiment with 6-7 mice per group. P values are determined 1-way ANOVA followed by Turkey multiple comparisons test (B) or log-rank test (C). * P < 0.05, ** P < 0.01, *** P < 0.001. significance between values indicated. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. by two-tailed Student's t-test or 1-way ANOVA. *P<0.05, **P <0.01, ***P <0.001, ****P < 0.0001.
